KNSA Kiniksa Pharmaceuticals International, plc

CIK 0001730430 24 ready 8-Ks latest May 26, 2026, 4:55 PM ET RSS · JSON

Activity: NORMAL 2 filings / 30d vs 1 baseline Risk accumulating: repeated leadership change (2)

Ready 8-Ks 24

Latest filing May 29, 2026, 4:35 PM ET

Top materiality 0.90

Event mix other_material ×11 · earnings ×9 · leadership ×3

Sentiment 10 pos · 0 neg · 14 neu

Latest earnings reported 2026-Q1

Executive change recent →

Recent 8-K filings for KNSA

Highest-materiality recent filing

Kiniksa Reports Q1 2026 ARCALYST Revenue of $214.3M, Raises 2026 Guidance to $930-$945M

April 28, 2026, 7:59 PM ET earnings materiality 0.90 positive item 2.02 item 9.01 ◈ Earnings Releases

ARCALYST Q1 2026 net product revenue $214.3 million, representing 56% year-over-year growth.
2026 ARCALYST net product revenue guidance raised to $930-$945 million from prior $900-$920 million.

Read filing →

May 26, 2026, 4:55 PM ET other material materiality 0.60 neutral item 1.01 item 9.01

Kiniksa caps Baker Bros. voting power at 49.9% by waiving conversion rights

Baker Bros. entities hold 12.78M A1 and 16.06M B1 shares; they waive conversion into A/B shares if ownership exceeds 49.9% voting rights.
April 28, 2026, 7:59 PM ET earnings materiality 0.90 positive item 2.02 item 9.01 ◈ Earnings Releases

Kiniksa Reports Q1 2026 ARCALYST Revenue of $214.3M, Raises 2026 Guidance to $930-$945M

ARCALYST Q1 2026 net product revenue $214.3 million, representing 56% year-over-year growth.
February 24, 2026, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Kiniksa reports Q4/FY 2025 net income; ARCALYST revenue up 62% to $677.6M; guides 2026 $900-920M

ARCALYST net product revenue $202.1M Q4, $677.6M FY 2025 (+62% YoY); gross-to-net improved to 8.4%.
January 14, 2026, 6:59 PM ET leadership materiality 0.60 neutral item 5.02

Kiniksa appoints Ross Moat as COO and Eben Tessari as Chief Strategy Officer

Ross Moat promoted to COO effective Jan 10, 2026; will oversee commercial and functional operations.
January 12, 2026, 6:59 PM ET other material materiality 0.75 positive item 2.02 item 9.01

Kiniksa 2025 ARCALYST revenue $677.5M (+62% YoY), guides 2026 to $900-920M

ARCALYST net product revenue $677.5M in 2025, up ~62% YoY from $417.0M in 2024.
October 28, 2025, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01

Kiniksa Q3 ARCALYST revenue $180.9M (+61% YoY); raises 2025 guidance to $670-675M

Net income $18.4M (vs loss $12.7M); cash $352.1M, no debt.
July 29, 2025, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01

Kiniksa Q2 ARCALYST revenue $156.8M (+52% YoY); raises 2025 guidance to $625-640M

ARCALYST net product revenue $156.8M in Q2 2025, up 52% from $103.4M in Q2 2024 (excl. $5.2M license revenue).
April 29, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Kiniksa Q1 2025 ARCALYST revenue $137.8M (+75% YoY); guides FY 2025 to $590-605M

ARCALYST net product revenue $137.8M in Q1 2025, up 75% YoY; net income $8.5M vs loss of $17.7M in Q1 2024.
February 25, 2025, 6:59 PM ET earnings materiality 0.75 neutral item 1.02 item 2.02 item 2.05 item 9.01

Kiniksa Q4 ARCALYST rev $122.5M ($417M FY); guides 2025 $560-580M; discontinues mavrilimumab & abiprubart

ARCALYST Q4 net product revenue $122.5M; full year $417.0M (79% YoY growth).
January 13, 2025, 6:59 PM ET other material materiality 0.80 positive item 2.02 item 9.01

Kiniksa reports 2024 ARCALYST net product revenue $416.4M (+79% YoY); guides 2025 to $560-580M

ARCALYST net product revenue: Q4 2024 $121.9M, FY 2024 $416.4M (unaudited), ~79% YoY growth.
October 29, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Kiniksa Q3 ARCALYST revenue $112.2M (+73% YoY); FY guidance raised to $410-420M

ARCALYST Q3 net product revenue $112.2M, up 73% YoY; FY 2024 guidance raised to $410-420M from $405-415M.
July 23, 2024, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01

Kiniksa Q2 ARCALYST revenue $103.4M (+90% YoY); 2024 guidance raised to $405-415M

ARCALYST net product revenue $103.4M in Q2 2024, up 90% YoY; ~11% of target 14,000 patients on therapy.
June 28, 2024, 7:59 PM ET other material materiality 0.70 neutral item 1.01 item 3.01 item 3.02 item 3.03 item 5.03 item 5.02 item 8.01 item 9.01

Kiniksa completes redomiciliation from Bermuda to UK, shares trade on Nasdaq under same symbol KNSA

Effective June 27, 2024, Kiniksa redomiciled to UK via Bermuda court-approved scheme of arrangement.
June 25, 2024, 7:59 PM ET other material materiality 0.60 neutral item 1.01 item 9.01

Kiniksa signs manufacturing agreement with Samsung Biologics for ARCALYST

Wholly-owned subsidiary entered MSA and PSA with Samsung Biologics for ARCALYST (rilonacept) drug substance.
April 23, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases

Kiniksa Q1 ARCALYST revenue $78.9M (+85% YoY); raises 2024 guidance to $370-390M

ARCALYST net product revenue $78.9M in Q1 2024, up 85% YoY; total revenue $79.9M vs $48.3M in Q1 2023.

Executive changes

Appointed

Eben Tessari

special advisor to the Company's Science and Research Committee

KNSA · Kiniksa Pharmaceuticals International, plc

Effective: 2026-05-15
Filed: May 1, 2026, 7:59 PM ET

Pursuant to a Consulting Agreement (the "Consulting Agreement") between Mr. Tessari and the Company, which will be effective as of May 15, 2026, Mr. Tessari will: (i) provide services to the Company related to strategic and operational matters and (ii) serve as a special advisor to the Company's Science and Research Committee (together, the "Services").

Departed

Eben Tessari

Chief Strategy Officer

KNSA · Kiniksa Pharmaceuticals International, plc

Effective: 2026-05-15
Filed: May 1, 2026, 7:59 PM ET

On April 30, 2026, Eben Tessari informed Kiniksa Pharmaceuticals International, plc (the "Company") of his decision to resign as Chief Strategy Officer of the Company to pursue another executive position within the life sciences industry.

Appointed

M. Cantey Boyd

Director

KNSA · Kiniksa Pharmaceuticals International, plc

Effective: 2024-10-04
Filed: October 7, 2024, 7:59 PM ET

the appointment of M. Cantey Boyd, age 44, to the Board to fill the vacancy created thereby

Earnings & guidance

2026-Q1 EPS reported $0.27 filing →

Materiality & sentiment trend

Max materiality 0.90 · Median 0.65 · Most common event other_material

10 positive 0 negative 14 neutral

source · KNSA on sec.gov